Podcasts about Gilead

The Guilty Feminist 473. Fascism Presented by Deborah Frances-White and Desiree Burch with special guest Professor Roger Griffin Recorded 20 February 2026 at the Museum of Comedy. Released 9 March. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have Donate to reproductive freedom, support MSI Reproductive Choices and visit msichoices.org More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Desiree Burch https://www.instagram.com/destheray https://www.desireeburch.com More about Roger Griffin https://www.brookes.ac.uk/profiles/staff/roger-griffin https://www.amazon.co.uk/Nature-Fascism-Roger-Griffin/dp/1138174084 For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT Come to a live show 31 March Bloomsbury Theatre. https://www.bloomsburytheatre.com/event/2026/03/guilty-feminist-live 30 April, Guilty Feminist x The Nerve. https://www.leicestersquaretheatre.com/show/guilty-feminist-x-the-nerve-road-to-gilead 10 April, 17 April, 14 May, 22 May Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 473. Fascism Presented by Deborah Frances-White and Desiree Burch with special guest Professor Roger Griffin Recorded 20 February 2026 at the Museum of Comedy. Released 9 March. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Desiree Burch https://www.instagram.com/destheray https://www.desireeburch.com More about Roger Griffin https://www.brookes.ac.uk/profiles/staff/roger-griffin https://www.amazon.co.uk/Nature-Fascism-Roger-Griffin/dp/1138174084 For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT Come to a live show 31 March Bloomsbury Theatre. https://www.bloomsburytheatre.com/event/2026/03/guilty-feminist-live 30 April, Guilty Feminist x The Nerve. https://www.leicestersquaretheatre.com/show/guilty-feminist-x-the-nerve-road-to-gilead 10 April, 17 April, 14 May, 22 May Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Sabiha Gati Guest: Thomas F. Luescher Want to watch that extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2556 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology this Week: A concise summary of recent studies The future of guidelines in an era of big data and AI Exercise in hypertrophic cardiomyopathy Snapshots Host: Sabiha Gati Guests: Kostas Koskinas, Thomas F. Luescher, Michael Papadakis, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2556 Want to watch the extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This teaching is taken from Proverbs 9:10-11 and teaches you about extending your life. If you have any questions, or you would like to share how our teachings have affected your life, please email us or visit us at rejoicingheart.net God bless you! Rob and Donna Rejoice In You From the Integrity Music Release One, featuring Planetshakers Ministries Int'l ©2009 Planetshakers Publishing (APRA) (admin. By Music Services, www.musicservices.org) All Rights Reserved. Used by permission. Proverbs 9:10-11 (KJV) 10 The fear of the LORD is the beginning of wisdom: and the knowledge of the holy is understanding. 11 For by me thy days shall be multiplied, and the years of thy life shall be increased. 1 Kings 3:12 (KJV) 12 Behold, I have done according to thy words: lo, I have given thee a wise and an understanding heart; so that there was none like thee before thee, neither after thee shall any arise like unto thee. Proverbs 1:7 (KJV) 7 The fear of the LORD is the beginning of knowledge: but fools despise wisdom and instruction. Proverbs 4:7 (KJV) 7 Wisdom is the principal thing; therefore get wisdom: and with all thy getting get understanding. Hosea 4:6 (KJV) 6 My people are destroyed for lack of knowledge: because thou hast rejected knowledge, I will also reject thee, that thou shalt be no priest to me: seeing thou hast forgotten the law of thy God, I will also forget thy children. James 1:17 (KJV) 17 Every good gift and every perfect gift is from above, and cometh down from the Father of lights, with whom is no variableness, neither shadow of turning. John 10:10 (KJV) 10 The thief cometh not, but for to steal, and to kill, and to destroy: I am come that they might have life, and that they might have it more abundantly. Psalm 91:16 (KJV) 16 With long life will I satisfy him, and shew him my salvation. Psalm 91:1 (KJV) 1 He that dwelleth in the secret place of the most High shall abide under the shadow of the Almighty. Proverbs 3:7-8 (KJV) 7 Be not wise in thine own eyes: fear the LORD, and depart from evil. 8 It shall be health to thy navel, and marrow to thy bones. Proverbs 4:20-22 (KJV) 20 My son, attend to my words; incline thine ear unto my sayings. 21 Let them not depart from thine eyes; keep them in the midst of thine heart. 22 For they are life unto those that find them, and health to all their flesh. Deuteronomy 34:1 (KJV) 1 And Moses went up from the plains of Moab unto the mountain of Nebo, to the top of Pisgah, that is over against Jericho. And the LORD shewed him all the land of Gilead, unto Dan, Deuteronomy 34:7 (KJV) 7 And Moses was an hundred and twenty years old when he died: his eye was not dim, nor his natural force abated. Proverbs 10:27 (KJV) 27 The fear of the LORD prolongeth days: but the years of the wicked shall be shortened.

On this week's episode, Tess Cameron, Josh Schimmer, Brian Skorney, and special guest Adam Feuerstein kick off with regulatory updates, including the FDA's rejection of Atara Biotherapeutics and Pierre Fabre Pharmaceuticals' cell therapy, Ebvallo -- a therapy that should have been approvable. The co-hosts then highlight ongoing inconsistencies at the agency and the challenge it creates for investors and companies as the regulatory goal posts continue to shift. Next, they discuss a New York Post editorial from the Alliance for Regenerative Medicine CEO Tim Hunt, who outlined how last‑minute reversals on rare disease and CGT approvals are leaving patients and biotech companies in limbo. The conversation then shifts to deals, including Gilead's $7.8B acquisition of Arcellx for full control of anito-cel for relapsed/refractory multiple myeloma, and Vir's pivot to oncology through a $1.7B collaboration with Astellas. In data news, the co-hosts cover CagriSema's head-to-head trial results against Lilly's Zepbound, Gossamer Bio's lung disease drug, seralutinib, which did not meet the primary endpoint in its Phase 3 pulmonary arterial hypertension study, and Palvella Therapeutics' positive topline results from the Phase 3 study of QTORIN rapamycin in microcystic lymphatic malformations. The episode closes with company updates, including Sarepta CEO Doug Ingram's retirement and Xenon Pharmaceuticals' upcoming seizure drug readout. *This episode aired on February 27, 2026.

In the industry news section of this week's episode, we kick things off with Tamarind Bio's efforts to develop user-friendly artificial intelligence tools for science researchers. Then we examine the impact of the U.S. Food and Drug Administration's reversal on its earlier refusal to review Moderna's mRNA vaccine for the flu, discuss Gilead's acquisition of Arcellx to expand its cancer therapy pipeline, and dive into Takeda's investment in Vir Biotech's prostate cancer candidate. Then on the research front, we get into the science behind new protein-like polymers engineered to target and degrade some of cancer's most challenging driver proteins. And we discuss a potential control switch for CAR T cells that could make these immunotherapies much safer. Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Uduak Thomas and Alex Philippidis for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: Tamarind Bio Secures $13.6M Series A to Make AI More Accessible for BiologyBy Fay Lin, PhD, GEN Edge, February 24, 2026 StockWatch: FDA Reversal Boosts Moderna, But Not Other Vaccine CompaniesBy Alex Philippidis, GEN Edge, February 21, 2026Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer PipelineBy Alex Philippidis, GEN Edge, February 23, 2026Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer CollaborationBy Alex Philippidis, GEN, February 26, 2026New Protein-Like Polymers Target, Degrade “Undruggable” Proteins Driving CancerGEN, February 11, 2026Drug-Controlled CAR T Cells May Enable Safer ImmunotherapyGEN, February 23, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.

Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Disease Week, providing draft guidance on its new plausible mechanism pathway, while a bipartisan senate hearing on Thursday will focus on the authorization process for rare conditions; Another leadership change shakes up CDC; and Gilead acquires CAR T partner Arcellx for nearly $8 billion.  Everything is coming up Lilly. The Indianapolis-based pharma bested its chief rival, Novo Nordisk in a head-to-head test. In a Phase 3 trial initiated by Novo itself, Lilly's Zepbound generated 25.5% weight loss while the Danish pharma's CagriSema elicited 23%. The results sent Novo's shares plummeting by an unprecedented 20% to a pre-Wegovy valuation while Lilly's market cap continues to climb.   Novo attempted a comeback on Tuesday, announcing that its triple-G agonist UBT251 scored almost 20% weight loss after 24 weeks in a Phase 2 trial in China. By comparison, Lilly's own triple-G competitor retatrutide led to 17.5% weight loss over the same timeframe, according to BMO Capital Markets analysts. Novo also sweetened the pot, announcing that it would slash the prices for all three of its GLP-1 medicines starting in 2027.    Meanwhile, the FDA kicked off Rare Disease Week with draft guidance on the new Plausible Mechanism Pathway for personalized therapies that was first teased in November. Jumping off last summer's Baby KJ success story, the new pathway is aimed at advancing treatments for ultra-rare diseases. And a bipartisan senate hearing on Thursday will focus on the authorization process for rare disease therapies.  While the rare disease space has enjoyed recent regulatory progress, funding these vital therapies remains a challenge. Companies like the Orphan Therapeutics Accelerator (OTXL), a non-profit biotech, are trying to change this with creative approaches including tax exempt status and unique partnerships with CDMOs and CMOs. Finally, in a move that also has implication for the rare disease space, the FDA's official pivot from a two clinical trial requirement to just one for new drug applications is lighting up biopharma social media.   And over at the CDC, there is more upheaval on the leadership front as National Institutes of Health Director Jay Bhattacharya replaces acting director Jim O'Neill as head of the agency, and principal deputy director Ralph Abraham steps down, citing “unforeseen family obligations.”    On the business front, Gilead inked the biggest M&A deal of the year so far, acquiring CAR T partner Arcellx for nearly $8B. And Merck's Keytruda should have a few extra years of dominance thanks to a web of patents, with billions on the line. Check it out in BioPharm Executive, in your inboxes Wednesday.  HostsJef Akst, Managing Editor, BioSpaceHeather McKenzie, Senior Editor, BioSpaceAnnalee Armstrong, Senior Editor, BioSpace

Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury's analysts assess what the deal does for the Foster City, Calif.-based biotech's pipeline.The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week's PhRMA Forum, which focused on China and the Trump administration's most favored nation (MFN) drug pricing policy, and on the lessons that can be drawn from FDA's about-face on the recent vaccine application from Moderna.View full story: https://www.biocentury.com/article/658516#BiotechMA #MultipleMyeloma #ctDNA #DrugPricingPolicy #FDA00:00 - Introduction02:34 - Gilead's Arcellx Buy11:14 - ctDNA Surrogate Endpoints21:59 - PhRMA Forum Takeaways29:19 - FDA Moderna U-turnTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Enttäuschung bei Novo Nordisk, Gileads Milliarden-Move und Übernahmefantasie bei Paypal. Außerdem geht es um Mongo DB, Zscaler, Datadog Doordash, American Express, Mastercard, Visa, Novo Nordisk, Eli Lilly, Gilead, Arcellx, Domino's, IBM, PayPal, BMW, VW, Mercedes-Benz, SAP, Infineon, Cloudflare, Crowdstrike, Zscaler, KKR, Blackstone, Apollo, GE Vernova, L&G Gold Mining ETF (WKN: A12CCL), L&G DAX Daily 2x Short (WKN: A0X8ZS), Amundi Core MSCI USA (WKN: ETF154), iShares MSCI USA (WKN: A0YEDU), SPDR S&P 500 (WKN: A3EUC1), UBS Core S&P 500 (WKN: A41DL0), SPDR S&P 500 Leaders (WKN: A2PSPE), iShares Core MSCI World (WKN: A0RPWH), Ark Innovation ETF (A14Y8H) und SPDR MSCI All Country World IMI (WKN: A1JJTD). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Wie steht's um deine Altersvorsorge? Kannst du dir jetzt bei Scalable Capital kostenlos ausrechnen: Mehr dazu hier. Zoll-Chaos drückt Märkte, Gold & China steigen. Wintersturm legt Airlines lahm. Software stürzt weiter. PayPal springt nach Übernahmegerücht. Gilead x Arcellx. Novo Nordisk crasht. Enel investiert. Lambo will kein E-Auto. IQM will an Börse. 20% Wachstum pro Jahr mit simplen Rohrverbindern? Reliance Worldwide (WKN: A2AHE7) dominiert mit der Marke SharkBite 85% des US-Marktes und ist das „Tesa“ der Klempner-Branche. 50% Rendite gab's für Südafrikas Leitindex letztes Jahr. Trotz 31% Arbeitslosigkeit. Wir schauen uns an, welche Rolle Player wie Shoprite (WKN: 853202), Capitec (WKN: 779555) oder Remgro (WKN: 578937) dabei spielen. Diesen Podcast vom 24.02.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

D'un côté, on a un Président américain en mode volcanique qui se mouche dans les décisions de la Cour Suprême pour imposer ses tarifs douaniers, quoi qu'il en coûte. De l'autre, une psychologie de marché qui a viré à la paranoïa pure : on ne cherche plus qui va PROFITER de l'IA, on cherche qui va se faire MASSACRER par elle en deuxième vague. Au menu ce matin : Tarifs Douaniers : Trump est fou de rage, l'Europe joue la montre et la Chine provoque. C'est le néant absolu aux douanes, mais le tiroir-caisse doit se remplir. Le krach des cols blancs : Citrini Research balance une bombe sur Substack et le secteur financier part à la cave. Et si l'IA ne vous aidait pas, mais vous remplaçait tout simplement ? Skynet & COBOL : Pourquoi IBM se fait démonter par Claude (Anthropic) et pourquoi votre banquier commence à transpirer. Technique : Le S&P 500 repasse sous sa moyenne mobile à 50 jours. Le vernis craque. Pharma & Shopping : Novo Nordisk puni pour 2% de gras en trop face à Eli Lilly, pendant que Gilead sort le carnet de chèques (7,8 milliards !). On termine avec le discours sur l'état de l'Union ce soir et la « messe » NVIDIA demain. En attendant, essayez de vous passer de votre IA une journée... avant qu'elle ne commence à vous donner des ordres. Bonne écoute et soyez forts !

The Guilty Feminist 471. The History of Queerphobia Presented by Deborah Frances-White and Abigoliah Schamaun with special guest Dr Harry Tanner Recorded 13 February 2026 at the Museum of Comedy in London. Released 23 February 2026. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Abigoliah Schamaun https://www.instagram.com/abigoliah https://abigoliah.com https://www.youtube.com/watch?v=rp1GBgUIMG4 https://linktr.ee/ndm_book https://podfollow.com/all-british-comedy-explained More about Dr Harry Tanner https://www.instagram.com https://harryjamestanner.com For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT Come to a live show Waterstone's Book Club, 23 February. https://www.waterstones.com/events/the-guilty-feminist-x-waterstones-book-club-jess-robinson-and-max-olesker/london-piccadilly Zack Polanski and Juno Dawson at The Union Chapel, 5 March. https://www.gigantic.com/the-guilty-feminist-tickets/london-union-chapel/2026-03-05-18-30 31 March Bloomsbury Theatre. https://www.bloomsburytheatre.com/event/2026/03/guilty-feminist-live Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 471. The History of Queerphobia Presented by Deborah Frances-White and Abigoliah Schamaun with special guest Dr Harry Tanner Recorded 13 February 2026 at the Museum of Comedy in London. Released 23 February 2026. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Abigoliah Schamaun https://www.instagram.com/abigoliah https://abigoliah.com https://www.youtube.com/watch?v=rp1GBgUIMG4 https://linktr.ee/ndm_book https://podfollow.com/all-british-comedy-explained More about Dr Harry Tanner https://www.instagram.com https://harryjamestanner.com For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT Come to a live show Waterstone's Book Club, 23 February. https://www.waterstones.com/events/the-guilty-feminist-x-waterstones-book-club-jess-robinson-and-max-olesker/london-piccadilly Zack Polanski and Juno Dawson at The Union Chapel, 5 March. https://www.gigantic.com/the-guilty-feminist-tickets/london-union-chapel/2026-03-05-18-30 31 March Bloomsbury Theatre. https://www.bloomsburytheatre.com/event/2026/03/guilty-feminist-live Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this RTB and Novel Dialogue episode from 2021, Helen Garner sits down with John and Elizabeth McMahon, a distinguished scholar of Australian literature. Helen's novels range from the anti-patriarchy exuberance of Monkey Grip (1977) to the heartbreaking mortality at the heart of The Spare Room (2008). She has also authored a slew of nonfiction, plus screenplays for Jane Campion's Two Friends and Gillian Armstrong's wonderfully Garneresque The Last Days of Chez Nous. After a reading from John's favorite, The Children's Bach, the trio discusses Garner's capacity for cutting and cutting, creating resonant, thought-inducing gaps. Garner connects that taste for excision, perhaps paradoxically, to her tendency to accumulate scraps, bits and pieces of life. She relates her father's restlessness to her own life-total of houses inhabited (27). “Why wouldn't I write about households?” asks Helen, “They're just so endlessly interesting.” Who shaped her writing? Raymond Carver: packed with power, but the pages white with omissions and excisions. Helen offers an anecdote about her own pruning that ends with her “ankle-deep in adverbs.” That's how to escape the “fat writing” that stems for distrust of the reader. She thoughtfully compares the practical virtues of keeping notebooks for the “music” of everyday life to the nightly process of diary-writing (more analytical). John raises the question of pervasive musical metaphors in Helen's writing, and she reports her passion for “boring pieces” and the “formal” side of Bach, which makes a listener feel that there is such a thing as meaning. “There's something about shaping a sentence, too, which can be musical.” Mentioned in the Episode Marilynne Robinson, Housekeeping (the fixed people and the wandering people), Gilead, Home, The West Wing (yes, the TV show! Helen watched it during lockdown when she couldn't bear fiction…) Raymond Carver‘s minimalist fiction (his first collection) Tess Gallagher (as writer and as Carver's editor) Willa Cather, “The Novel Démeublé” (1922; on how to un-furnish fiction, leaving it an empty room) Ernest Hemingway, A Moveable Feast Sigmund Freud on “the day's residue” (e.g. in The Interpretation of Dreams, 1900) George Eliot, Quarry for Middlemarch Listen to Episode Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In this RTB and Novel Dialogue episode from 2021, Helen Garner sits down with John and Elizabeth McMahon, a distinguished scholar of Australian literature. Helen's novels range from the anti-patriarchy exuberance of Monkey Grip (1977) to the heartbreaking mortality at the heart of The Spare Room (2008). She has also authored a slew of nonfiction, plus screenplays for Jane Campion's Two Friends and Gillian Armstrong's wonderfully Garneresque The Last Days of Chez Nous. After a reading from John's favorite, The Children's Bach, the trio discusses Garner's capacity for cutting and cutting, creating resonant, thought-inducing gaps. Garner connects that taste for excision, perhaps paradoxically, to her tendency to accumulate scraps, bits and pieces of life. She relates her father's restlessness to her own life-total of houses inhabited (27). “Why wouldn't I write about households?” asks Helen, “They're just so endlessly interesting.” Who shaped her writing? Raymond Carver: packed with power, but the pages white with omissions and excisions. Helen offers an anecdote about her own pruning that ends with her “ankle-deep in adverbs.” That's how to escape the “fat writing” that stems for distrust of the reader. She thoughtfully compares the practical virtues of keeping notebooks for the “music” of everyday life to the nightly process of diary-writing (more analytical). John raises the question of pervasive musical metaphors in Helen's writing, and she reports her passion for “boring pieces” and the “formal” side of Bach, which makes a listener feel that there is such a thing as meaning. “There's something about shaping a sentence, too, which can be musical.” Mentioned in the Episode Marilynne Robinson, Housekeeping (the fixed people and the wandering people), Gilead, Home, The West Wing (yes, the TV show! Helen watched it during lockdown when she couldn't bear fiction…) Raymond Carver‘s minimalist fiction (his first collection) Tess Gallagher (as writer and as Carver's editor) Willa Cather, “The Novel Démeublé” (1922; on how to un-furnish fiction, leaving it an empty room) Ernest Hemingway, A Moveable Feast Sigmund Freud on “the day's residue” (e.g. in The Interpretation of Dreams, 1900) George Eliot, Quarry for Middlemarch Listen to Episode Learn more about your ad choices. Visit megaphone.fm/adchoices

In this RTB and Novel Dialogue episode from 2021, Helen Garner sits down with John and Elizabeth McMahon, a distinguished scholar of Australian literature. Helen's novels range from the anti-patriarchy exuberance of Monkey Grip (1977) to the heartbreaking mortality at the heart of The Spare Room (2008). She has also authored a slew of nonfiction, plus screenplays for Jane Campion's Two Friends and Gillian Armstrong's wonderfully Garneresque The Last Days of Chez Nous. After a reading from John's favorite, The Children's Bach, the trio discusses Garner's capacity for cutting and cutting, creating resonant, thought-inducing gaps. Garner connects that taste for excision, perhaps paradoxically, to her tendency to accumulate scraps, bits and pieces of life. She relates her father's restlessness to her own life-total of houses inhabited (27). “Why wouldn't I write about households?” asks Helen, “They're just so endlessly interesting.” Who shaped her writing? Raymond Carver: packed with power, but the pages white with omissions and excisions. Helen offers an anecdote about her own pruning that ends with her “ankle-deep in adverbs.” That's how to escape the “fat writing” that stems for distrust of the reader. She thoughtfully compares the practical virtues of keeping notebooks for the “music” of everyday life to the nightly process of diary-writing (more analytical). John raises the question of pervasive musical metaphors in Helen's writing, and she reports her passion for “boring pieces” and the “formal” side of Bach, which makes a listener feel that there is such a thing as meaning. “There's something about shaping a sentence, too, which can be musical.” Mentioned in the Episode Marilynne Robinson, Housekeeping (the fixed people and the wandering people), Gilead, Home, The West Wing (yes, the TV show! Helen watched it during lockdown when she couldn't bear fiction…) Raymond Carver‘s minimalist fiction (his first collection) Tess Gallagher (as writer and as Carver's editor) Willa Cather, “The Novel Démeublé” (1922; on how to un-furnish fiction, leaving it an empty room) Ernest Hemingway, A Moveable Feast Sigmund Freud on “the day's residue” (e.g. in The Interpretation of Dreams, 1900) George Eliot, Quarry for Middlemarch Listen to Episode Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

In this RTB and Novel Dialogue episode from 2021, Helen Garner sits down with John and Elizabeth McMahon, a distinguished scholar of Australian literature. Helen's novels range from the anti-patriarchy exuberance of Monkey Grip (1977) to the heartbreaking mortality at the heart of The Spare Room (2008). She has also authored a slew of nonfiction, plus screenplays for Jane Campion's Two Friends and Gillian Armstrong's wonderfully Garneresque The Last Days of Chez Nous. After a reading from John's favorite, The Children's Bach, the trio discusses Garner's capacity for cutting and cutting, creating resonant, thought-inducing gaps. Garner connects that taste for excision, perhaps paradoxically, to her tendency to accumulate scraps, bits and pieces of life. She relates her father's restlessness to her own life-total of houses inhabited (27). “Why wouldn't I write about households?” asks Helen, “They're just so endlessly interesting.” Who shaped her writing? Raymond Carver: packed with power, but the pages white with omissions and excisions. Helen offers an anecdote about her own pruning that ends with her “ankle-deep in adverbs.” That's how to escape the “fat writing” that stems for distrust of the reader. She thoughtfully compares the practical virtues of keeping notebooks for the “music” of everyday life to the nightly process of diary-writing (more analytical). John raises the question of pervasive musical metaphors in Helen's writing, and she reports her passion for “boring pieces” and the “formal” side of Bach, which makes a listener feel that there is such a thing as meaning. “There's something about shaping a sentence, too, which can be musical.” Mentioned in the Episode Marilynne Robinson, Housekeeping (the fixed people and the wandering people), Gilead, Home, The West Wing (yes, the TV show! Helen watched it during lockdown when she couldn't bear fiction…) Raymond Carver‘s minimalist fiction (his first collection) Tess Gallagher (as writer and as Carver's editor) Willa Cather, “The Novel Démeublé” (1922; on how to un-furnish fiction, leaving it an empty room) Ernest Hemingway, A Moveable Feast Sigmund Freud on “the day's residue” (e.g. in The Interpretation of Dreams, 1900) George Eliot, Quarry for Middlemarch Listen to Episode Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literature

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial septal defects in adults Conservative and invasive management of chronic coronary syndromes Milestones: 4S trial   Host: Rick Grobbee Guests: JP Carpenter, Annemien van den Bosch, Rasha Al-Lamee, Roxana Mehran Want to watch the episode? Go to: https://esc365.escardio.org/event/2552 Want to watch the extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; personal fees from: None ; Equity

Host: Rick Grobbee Guest: Annemien van den Bosch Want to watch that extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2552 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson

In this RTB and Novel Dialogue episode from 2021, Helen Garner sits down with John and Elizabeth McMahon, a distinguished scholar of Australian literature. Helen's novels range from the anti-patriarchy exuberance of Monkey Grip (1977) to the heartbreaking mortality at the heart of The Spare Room (2008). She has also authored a slew of nonfiction, plus screenplays for Jane Campion's Two Friends and Gillian Armstrong's wonderfully Garneresque The Last Days of Chez Nous. After a reading from John's favorite, The Children's Bach, the trio discusses Garner's capacity for cutting and cutting, creating resonant, thought-inducing gaps. Garner connects that taste for excision, perhaps paradoxically, to her tendency to accumulate scraps, bits and pieces of life. She relates her father's restlessness to her own life-total of houses inhabited (27). “Why wouldn't I write about households?” asks Helen, “They're just so endlessly interesting.” Who shaped her writing? Raymond Carver: packed with power, but the pages white with omissions and excisions. Helen offers an anecdote about her own pruning that ends with her “ankle-deep in adverbs.” That's how to escape the “fat writing” that stems for distrust of the reader. She thoughtfully compares the practical virtues of keeping notebooks for the “music” of everyday life to the nightly process of diary-writing (more analytical). John raises the question of pervasive musical metaphors in Helen's writing, and she reports her passion for “boring pieces” and the “formal” side of Bach, which makes a listener feel that there is such a thing as meaning. “There's something about shaping a sentence, too, which can be musical.” Mentioned in the Episode Marilynne Robinson, Housekeeping (the fixed people and the wandering people), Gilead, Home, The West Wing (yes, the TV show! Helen watched it during lockdown when she couldn't bear fiction…) Raymond Carver‘s minimalist fiction (his first collection) Tess Gallagher (as writer and as Carver's editor) Willa Cather, “The Novel Démeublé” (1922; on how to un-furnish fiction, leaving it an empty room) Ernest Hemingway, A Moveable Feast Sigmund Freud on “the day's residue” (e.g. in The Interpretation of Dreams, 1900) George Eliot, Quarry for Middlemarch Listen to Episode Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/australian-and-new-zealand-studies

Audio roundup of selected biopharma industry content from Scrip over the business week ended February 13, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Scrip Asks on R&D Innovation; Bayer's “paradigm-changing” stroke results; AstraZeneca's precision oncology approach; Gilead's CMO reflects on pipeline; and India's pharma chiefs on driving innovation. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-EP6IJB43CRG7XBFEWVVN7V3FXE/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

European bourses are mostly firmer, US equity futures are flat/incrementally higher.DXY is flat awaiting Retail Sales/ECI, JPY bid alongside JGB stabilisation whilst NOK gains post-inflation.Fixed rebounds from Monday's pressure into data & supply; Gilts outperform as PM Starmer pushed back on calls to resign.WTI and Brent mildly lower, XAU remains above USD 5k/oz; Copper muted heading into Chinese festive period.Looking ahead, highlights include US NFIB (Jan), Weekly ADP, ECI (Q4), Retail Sales (Dec) & EIA STEO. Speakers include Fed's Hammack & Logan, Supply from the US. Earnings from Coca-Cola, S&P, Gilead, Robinhood, Welltower, Datadog, Ford, AIG, Xylem.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

APAC stocks were mostly higher as the region took impetus from the gains on Wall Street, where the S&P 500 approached closer towards its record levels, and the Nasdaq outperformed as the tech rebound persisted.US President Trump and Chinese President Xi's summit is reportedly set for the first week of April, POLITICO reported, but the White House later clarified that the Trump-Xi meeting has not been finalised.The EU is reportedly readying options to give Ukraine gradual membership rights and is preparing a series of options to embed Ukraine's membership in a future peace deal.UK PM Starmer told Labour MPs that he is "not prepared to walk away" from power or "plunge us into chaos" as previous prime ministers have done.European equity futures indicate a slightly lower cash market open with Euro Stoxx 50 futures down 0.1% after the cash market closed with gains of 1.0% on Monday.Looking ahead, highlights include Norwegian CPI (Jan), US NFIB (Jan), Weekly ADP, ECI (Q4), Retail Sales (Dec) & EIA STEO. Speakers include Fed's Hammack & Logan, Supply from the Netherlands, UK, Germany & US. Earnings from Coca-Cola, S&P, Gilead, Robinhood, Welltower, Duke Energy, Datadog, Ford, AIG, Xylem, Spotify, AstraZeneca, BP, Barclays, Ferrari and Mediobanca.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Arcellx. She also discusses cell therapy funding cycles and big pharma, the autologous versus allogeneic divide, why in vivo CAR-T therapies could be a game changer, what the FDA's focus on cell and gene therapies could mean for U.S. competition, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a fascinating array of stories that highlight the scientific advancements, regulatory updates, and strategic maneuvers shaping our industry.Let's begin with Biogen's efforts to breathe new life into its spinal muscular atrophy treatment, Spinraza. In response to declining sales, Biogen is launching a high-dose version in Japan, aiming to enhance therapeutic efficacy and regain market competitiveness. This move underscores the company's strategy to offset projected revenue declines by 2026. The decision to pursue this high-dose version reflects Biogen's commitment to maintaining its foothold in a challenging market landscape where innovation is key to survival.Shifting gears to regulatory news, the FDA, led by Commissioner Marty Makary, has taken a firm stance against the proliferation of illegal copycat drugs. This announcement comes on the heels of Hims & Hers' controversial introduction of a compounded version of Novo Nordisk's obesity drug, Wegovy. The FDA's commitment to protecting intellectual property and patient safety is crucial in an era where health tech firms increasingly challenge traditional pharmaceutical boundaries. Novo Nordisk's aggressive marketing strategy for Wegovy, including a high-profile Super Bowl advertisement, highlights the competitive pressures in this growing market segment and underscores the legal tensions between established pharma giants and emerging tech-driven companies.In an unexpected turn of events, BridgeBio faced a significant setback as Pfizer withdrew its tafamidis patent in Europe. This led to a notable drop in BridgeBio's stock price and raised concerns about earlier generic entries into the ATTR-CM market. Such developments signal potential shifts in market dynamics and pricing strategies that companies must navigate carefully.On the clinical front, Bayer's phase 3 study of asundexian has demonstrated remarkable results—a 26% reduction in stroke risk. This positions Bayer favorably against competitors Bristol Myers Squibb and Johnson & Johnson, setting a new benchmark in the high-stakes anticoagulant market. Innovation continues to be paramount as companies strive for superior clinical outcomes that can significantly impact patient care.Regulatory landscapes are evolving as well, with Gilead's Yescarta receiving clearance for expanded use. These milestones are crucial for broadening therapeutic indications and enhancing patient access, underscoring ongoing efforts to address unmet medical needs while sustaining growth trajectories.Meanwhile, Pfizer-backed Priovant has reported promising mid-stage results for brepocitinib in treating dermatomyositis and other rare skin conditions. As a TYK2/JAK1 inhibitor, brepocitinib exemplifies precision medicine's expanding role in addressing autoimmune disorders through targeted therapies.The IPO scene remains vibrant with Agomab Therapeutics and Spyglass Pharma making substantial entries into Nasdaq, collectively raising $350 million. This influx indicates continued investor confidence in biopharma innovation despite broader economic uncertainties—a testament to the sector's resilience and potential for groundbreaking advancements.Corporate dynamics are also shifting as seen with Moderna's Chief Medical Officer Jacqueline Miller stepping down after a brief tenure. Leadership changes such as these often signal strategic realignments within companies as they adapt to complex regulatory environments and competitive pressures.Summarizing these developments illustrates a dynamic landscape marked by scientific innovation, regulatory vigilance, and strategic marketing initiatives. As companies strive for competitive advantage through new drug formulations and market expansions, they must also navigate legal challenges and regSupport the show

This episode covers: Cardiology This Week: A concise summary of recent studies Lp(a) and aortic valve stenosis The truth about climate change and heart disease Snapshots Host: Emer Joyce Guests: JP Carpenter, Borge Nordestgaard, Hugh Montgomery, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2548 Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1.  Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Hugh Montgomery has declared to have potential conflicts of interest to report: funded and runs the charity-funded non-profit 'Real Zero'. Unpaid co-chair of the UK Health Alliance on Climate Change, Lancet Countdown on Health and Climate Change. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Borge Nordestgaard Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2548 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

The December 2025 JW Broadcast features the Gilead graduation ceremony, including talks from King Stephen Lett and Real Estate Investor King Jodi Jedele. Listen in as we discuss how salty all the graduates are and what it means when someone asks you for a fire extinguisher!TWITTER: @exjwpodcastINSTAGRAM: survivingparadisepodcast

Welcome to Day 2787 of Wisdom-Trek. Thank you for joining me. This is Guthrie Chamberlain, Your Guide to Wisdom. Day 2787 – Wisdom Nuggets – Psalm 108:10-13 – Daily Wisdom Wisdom-Trek Podcast Script - Day 2787 Welcome to Wisdom-Trek with Gramps! I am Guthrie Chamberlain, and we are on Day two thousand seven hundred eighty-seven of our Trek. The Purpose of Wisdom-Trek is to create a legacy of wisdom, to seek out discernment and insights, and to boldly grow where few have chosen to grow before. The Title for Today's Wisdom-Trek is: The Divine Stomp – Storming the Gates of the Impossible.   Today, we arrive at the grand finale of our journey through Psalm One Hundred Eight. We are trekking through the final stanza, verses ten through thirteen, in the New Living Translation. In our previous trek, we stood in the War Room of Heaven. We heard the Divine Oracle in verses six through nine, where Yahweh looked at the map of the Middle East and claimed His territory. We heard Him declare, "Gilead is mine... Manasseh is mine... Moab is my washbasin... I will wipe my feet on Edom." It was a breathtaking assertion of ownership. We saw God claiming the hostile nations as His servants—His washpots and His shoe-racks. It was a moment of high theology and divine confidence. But today, the scene shifts from the map on the wall to the mud on the ground. In Psalm One Hundred Eight, verses ten through thirteen, King David takes that divine promise and tries to walk it out in the real world. And he immediately hits a wall—literally. He finds himself standing outside the "fortified city" of Edom. The map says Edom belongs to God. But the reality says Edom is locked up tight behind impregnable walls. This is where the rubber meets the road in our spiritual lives. It is one thing to sing about victory in the sanctuary; it is another thing to secure it on the battlefield. It is one thing to believe God owns the problem; it is another to see Him conquer it. In these final four verses, we will see the transition from Promise to Petition, and finally to Participation. We will learn that the only way to breach the fortified city is to abandon human strategies and rely on the Divine Warrior to do the trampling. So, let us draw our swords one last time and march toward the gate. The first segment is: The Crisis of Geography: The Impregnable City. Psalm One Hundred Eight: verse ten. Who will bring me into the fortified city? Who will bring me to Edom? The psalm moves from God's voice back to David's voice. And David has a logistical problem. God just said in verse nine: "I will wipe my feet on Edom."   David responds: "Okay, Lord. But who is going to get me inside?" "Who will bring me into the fortified city? Who will bring me to Edom?" To understand the weight of this question, we have to look at the geography. The ancient capital of Edom was Bozrah, and later Petra (Sela). Edom was legendary for its natural defenses. It was carved into the red sandstone cliffs. The only way in was through a narrow canyon called the Siq. It was a natural fortress that armies broke themselves against for centuries. It was the "Fortified City" (Ir Mibzar) par excellence. When David

Welcome to Day 2785 of Wisdom-Trek. Thank you for joining me. This is Guthrie Chamberlain, Your Guide to Wisdom. Day 2785 – Wisdom Nuggets – Psalm 108:6-9 – Daily Wisdom Wisdom-Trek Podcast Script - Day 2785 Welcome to Wisdom-Trek with Gramps! I am Guthrie Chamberlain, and we are on Day two thousand seven hundred eighty-five of our Trek. The Purpose of Wisdom-Trek is to create a legacy of wisdom, to seek out discernment and insights, and to boldly grow where few have chosen to grow before. The Title for Today's Wisdom-Trek is: The Divine Cartography – God Claims His Geography. Today, we are back on the trail, continuing our exploration of the "Warrior Poet's Remix," Psalm One Hundred Eight. We are trekking through the middle section, verses six through nine, in the New Living Translation. In our previous trek through the first five verses of this psalm, we heard the sound of a "fixed heart." We watched King David wake the dawn with his lyre and declare that God's love is higher than the heavens. We saw him take an old song of lament (from Psalm Fifty-seven) and remix it into a new anthem of confidence. He ended that section with a cosmic prayer: "Be exalted, O God, above the highest heavens. May your glory shine over all the earth." Today, the scene shifts from the cosmic to the concrete. David moves from singing about the stars to looking at a map. He moves from the "heavens" to the dirt and rock of the Middle East. In verses six through nine, we hear God Himself speak. It is a divine oracle spoken from the Holy Sanctuary. In this oracle, Yahweh acts like a victorious General standing over a map of the ancient Near East. He points to specific territories—Shechem, Succoth, Gilead, Moab, Edom, Philistia—and claims them as His own. He essentially says, "This belongs to Me. And this belongs to Me. And that over there? That is just My washbasin." This is a powerful assertion of Divine Ownership. In the Ancient Israelite worldview, where nations were believed to be owned by their respective gods (Chemosh for Moab, Milcom for Ammon), Yahweh is declaring that He is the Landlord of everything. He is redrawing the borders and reclaiming the inheritance for His people. So, let us stand in the war room and listen to the strategy of the King. The first segment is: The Prayer for Rescue: The Right Hand of Power. Psalm One Hundred Eight: verse six. Now rescue your beloved people. Answer and save us by your power. Before the oracle begins, David offers a short, sharp prayer. This acts as the bridge between the praise of the first five verses and the prophecy that follows. "Now rescue your beloved people. Answer and save us by your power." The literal Hebrew here is quite evocative: "That Your beloved ones may be delivered; Save with Your right hand, and answer me!" First, notice the identity of the people. David calls them "Your beloved people" (yedid-echa). This comes from the same root as the name Jedidiah (which was Solomon's name given by God, meaning "Beloved of Yahweh"). This is crucial for our confidence in prayer. David doesn't appeal to God based on Israel's military strength or their moral perfection. He appeals to God's affection. "Lord, these are the ones You love. Therefore, rescue them." Second, notice the method...

Join Melissa Berry as she welcomes Annie Bond, metastatic breast cancer thriver, advocate, and comedian, to share her first-time experience at SABCS 2025. Together, they explore the moments, conversations, and insights that matter most for metastatic patients and advocates, focusing on advocacy, representation, and the power of patient voices. This episode highlights the urgent need for more data and research in metastatic breast cancer and shows how patient advocacy can drive meaningful change. As part of the "Your Guide to SABCS" series, produced with the Triple Negative Breast Cancer Foundation and TOUCH The Black Breast Cancer Alliance, this episode offers a patient-led perspective on SABCS, demonstrating that the conference is about more than science. It emphasizes advancing metastatic breast cancer research and elevating the voices of those living with the disease. Thank you to BioNtech, Lilly, Gilead, AstraZeneca and Pfizer for making this episode possible.

This episode covers: Cardiology This Week: A concise summary of recent studies What´s new in TAVI?  Digital solutions in arrhythmias Mythbusters - Gratitude is heart healthy Host: Emer Joyce Guests: JP Carpenter, Davide Capodanno, Fleur Tjong Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Want to watch that extended interview on Digital solutions in arrhythmias, go to: https://esc365.escardio.org/event/2528?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Host: Emer Joyce Guest: Fleur Tjong Want to watch that extended interview on https://esc365.escardio.org/event/2528?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Francesca Samsel is crafting a new language for our world. That is, she crosses art, science, and visualization to open new ways of understanding and engaging with the natural world, not just visually but across the sensorial spectrum. She recognizes the inextricably social element to this, too, and her work raises our capacity to collaborate, and in the process, alters our sense of what scientific inquiry is and can (and perhaps needs to) be. Her work as her life are teachers we need for the world we are walking into. Origins Podcast WebsiteFlourishing Commons NewsletterShow Notes:vulnerability (11:30)problem with the 'follow your passion' path (14:20)Ganymede (15:00)what she tells her students (15:50)art-science collaboration (16:00)Santa Fe Institute (21:20)James (Jim) Ahrens (24:00)Craig Tweedie (25:20)visual structure to see the complexity in data (29:00)Isaac Asimov 'that's funny' (30:20)the need for scientific breakthrough (31:20)Lia Halloran - your hand will physically guide you the way to breakthrough (31:30)the only mark that you determine as an artist is the first one (33:00)delivery-oriented society (34:30)"Stewardship of Global Collective Behavior" by Joseph Bak-Coleman et al. (40:00)visual vocabulary work (42:00)Art-Sci-Vis Lab at UT Austin (43:20)flourishing (47:00)Gilead by Marilynne Robinson (51:45)lightning round (48:00)Artist: Jon McCormick (work called "Fifty Sisters")Passion: geoscience and the complexity you find when you walk out of the doorHeart sing: fused glass, ice, and rockScrewed up: obliviousness to colleaguesFind Francesca online:Website UT AustinLogo artwork by Cristina GonzalezMusic by swelo on all streaming platforms or @swelomusic on social media

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by rapid transformations and strategic maneuvers that are reshaping the industry.Novo Nordisk is at a pivotal point under the leadership of CEO Maziar Mike Doustdar. The company is navigating a significant transition, focusing on reclaiming its leadership in the glucagon-like peptide-1 (GLP-1) market. This is crucial as GLP-1 receptor agonists are central to diabetes and obesity treatments, areas where Novo Nordisk aims to solidify its presence amidst fierce competition.AstraZeneca is setting ambitious targets, aiming for $80 billion in revenue by 2030. Their confidence is buoyed by strong Phase 3 clinical trial performances, particularly in oncology and rare diseases, underscoring the importance of a robust and successful pipeline. AstraZeneca's acquisition of Modella AI marks an integration of advanced AI models into oncology R&D operations, aligning with industry trends leveraging AI for drug discovery processes. By incorporating AI technologies, AstraZeneca aims to revolutionize precision medicine approaches within oncology treatments.Travere Therapeutics finds itself at a critical juncture with the FDA's delayed decision on Filspari (sparsentan) for focal segmental glomerulosclerosis (FSGS). This potential approval could tap into a significant market opportunity, but the delay highlights regulatory challenges that can impact timelines and revenue forecasts.Gilead Sciences continues to strengthen its position in HIV treatment with lenacapavir's approval for bi-annual dosing. This advancement not only enhances patient compliance but also positions Gilead advantageously for strategic partnerships. Their strategic positioning post-approval of lenacapavir for HIV prevention marks a milestone, emphasizing innovation's role in drug formulations.Leo Pharma's pursuit of partnerships in rare dermatological diseases reflects a broader trend towards specialization and diversification into niche markets. Meanwhile, Ionis Pharmaceuticals is gearing up to launch Tryngolza (olezarsen) for new indications, doubling their sales projections and demonstrating confidence in their RNA-targeted therapy.Caldera's emergence with significant funding points to ongoing investor interest in innovative biotech ventures, particularly those involving cross-border collaborations like their licensed drug from China for inflammatory bowel disease. Cross-border collaborations such as Caldera's venture into inflammatory bowel disease treatments are becoming more prevalent, integrating innovations from different regions to accelerate novel therapy availability for complex diseases.Illumina's efforts to navigate export challenges with China highlight geopolitical factors influencing biotech operations and global supply chains. They are actively working to stabilize their business environment while supporting academic research initiatives. Illumina's collaboration efforts with China amidst geopolitical tensions further demonstrate complexities within international trade relations affecting scientific collaborations.The American Medical Association's investment in "precision education" using data analytics exemplifies how technology is reshaping healthcare education and practice, aiming to enhance outcomes by tailoring learning experiences.AbbVie has committed $100 billion to U.S. research and development over the next decade, focusing on biologics and autoimmune disorders. This substantial investment underscores their commitment to innovation while seeking competitive edge enhancements through tariff exemptions.On clinical fronts, significant advancements are being made in therapies targeting rare diseases such as Sentynl Therapeutics' FDA approval for Zycubo—a novel protein therapy addressing Menkes disease—highlightSupport the show

Broadcast from KSQD, Santa Cruz on 1-01-2025: An emailer asks about omega-3 supplementation for memory at age 72. Dr. Dawn advises checking that fish oil capsules contain adequate DHA—at least 1,000 mg—since many omega-3 products have low DHA levels. She notes Medicare covers the same testing at standard labs as proprietary labs like OmegaQuant that charge patients directly. Beyond omega-3s, she emphasizes glucose control (hemoglobin A1c below 5.6) since the enzyme that breaks down insulin also clears beta-amyloid, and weight training to raise brain-derived neurotrophic factor (BDNF), which promotes new synapse formation essential for memory. Dr. Dawn reviews Popular Science's top 2025 health innovation: eye drops from Lens Therapeutics containing aceclidine that correct age-related farsightedness for 10 hours. The drops shrink the pupil to increase depth of field, improving near vision by three or more lines on eye charts within 30 minutes without affecting distance vision. Side effects include eye irritation, dimmed night vision, and headache. She describes Duke University's breakthrough allowing heart transplants from circulatory death donors using an on-table reanimation technique. This could expand the pediatric donor pool by 20%—critical since up to 20% of children die waiting for transplants. Dr. Dawn celebrates CAR-T immunotherapy for multiple myeloma, which saved her husband's life. Of 97 heavily pretreated patients, 38% achieved complete remission still present at five years, with over 50% total survival. The therapy removes T-cells, uses CRISPR to add receptors targeting cancer cell antigens, then reinfuses the modified cells. She highlights a UC Davis study showing remote blood pressure monitoring with home technology, education, and coaching dropped patients' average blood pressure from 150/80 to 125/74 in months—low-tech with high impact. Dr. Dawn explains the Nano Knife for prostate cancer, which uses localized electrical pulses delivered through thin wires to destroy tumors while sparing surrounding nerves. This minimally invasive approach could reduce erectile dysfunction and incontinence common with traditional surgery. She describes Gilead's Sunlenca, a twice-yearly injection for HIV prevention that's 99% effective. At $14,000 per injection in the US, proceeds help fund access in resource-limited countries where it can be distributed like a vaccination. Dr. Dawn discusses Journavx (suzetrigine), a new non-opioid pain medication working on sodium channels to block pain signals before reaching the brain. At $30 for 50 pills on GoodRx, it offers an alternative for surgical pain in patients with addiction history or genetic vulnerability to opioid dependence. She details the landmark case of Baby KJ, the first person to receive personalized CRISPR gene therapy. Born with a CPS1 enzyme deficiency causing toxic ammonia buildup, KJ was too small for liver transplant. Scientists identified his specific mutation and used CRISPR base editing delivered via lipid nanoparticles to correct a single DNA letter—changing an A to G—in his liver cells which restored enough function to be discharged home. Dr. Dawn reports surprising findings that COVID mRNA vaccines amplify cancer immunotherapy. Lung cancer patients who received COVID vaccination within 100 days of checkpoint inhibitor treatment had 56% three-year survival versus 31% for unvaccinated patients. The mechanism is unknown but may involve mRNA generally alerting the immune system. She revisits research showing Zostavax shingles vaccination reduced dementia risk by 20% over seven years. A natural experiment in Wales—where an age cutoff created comparable vaccinated and unvaccinated groups—provided strong evidence that preventing herpes zoster inflammation protects brain health. Dr. Dawn concludes with Huntington's disease breakthrough: microRNA therapy delivered by virus directly into the brain slowed disease progression by 75% over three years. The microRNA binds to Huntington protein mRNA, preventing ribosome translation and toxic protein production. Some patients returned to work; others expected to need wheelchairs are still walking.

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

Gilead Girls: Building a Tallow-Based Skincare Business from ScratchIn this episode of 'Small Town Big Business,' hosts Jennifer Olson and Russell Williams interview Abby Jurgens and Megan Adams from Gilead Girls, a small business that produces tallow-based skincare products. Abby and Megan share the origins of their business, which started as a solution to personal health issues and evolved into a popular brand. The conversation covers their product development process, sourcing local ingredients, the challenges of entrepreneurship, and their passion for educating others on the benefits of natural products. The episode also features exciting news about Gilead Girls taking over Good Life Nutrition in Marion, Illinois.00:00 Welcome to Small Town Big Business00:50 Meet Our Special Guests: Abby and Megan from Gilead Girls01:01 The Journey of Gilead Girls: From Friendship to Business02:00 Discovering Tallow: The Healing Journey05:51 From Side Hustle to Market Success09:52 Challenges and Triumphs in Business13:38 The Healing Power of Tallow17:51 Overcoming Business Hurdles20:03 The Importance of Knowing Your Source20:48 Challenges with Pricing and Market Adaptation21:10 Expanding the Team and Overcoming Local Challenges23:22 Building Relationships with Local Farms23:58 Success in Local Stores and Community Impact25:50 Family Involvement and Entrepreneurial Spirit27:31 Future Growth and Exciting Announcements31:15 Educational Resources and Inspirations32:28 Accessing Our Products and Community Engagement36:07 Final Thoughts and GratitudeRecorded at EThOs Small Business Incubator and Co-working Spaces in Marion, Illinois.https://members.ethosmarion.org/ SUBSCRIBE TO THE PODCASTOur guest: https://www.facebook.com/profile.php?id=100093612317425SPECIAL THANK YOU TO OUR SPONSORS:Watermark Auto Group: https://www.watermark.auto/Fowler Heating & Cooling: https://fowlerheatingandcooling.com/Swinford Media Group: https://swinfordpublications.com/Arcadia Wealth Group: https://www.raymondjames.com/arcadiawealthgroupBanterra Bank: https://www.banterra.bank/Southern Illinois Now: https://southernillinoisnow.org/Produced by Union Street Artshttps://www.unionstreetarts.com/

Dr. Tom Curran reflects on scripture passages that will transform your life. Tom shares several insights from Song of Songs chapters 4-6 about how much Jesus loves YOU!You have ravished my heart, my sister, my bride; you have ravished my heart with one glance of your eyes, with one bead of your necklace. (Song of Songs 4: 9)Turn your eyes away from me, for they stir me up. Your hair is like a flock of goats streaming down from Gilead. (Song of Songs 6: 5)

The Guilty Feminist 464. Reform's Ties to the ADF Presented by Deborah Frances-White and Susan Wokoma and special guest Jane Bradley. Recorded 23 November 2025 at The Bill Murray Comedy Club. Released 5 January. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Susan Wokoma https://www.instagram.com/susiewoosie12 https://www.instagram.com/p/DFK7aZDI5Sb More about Jane Bradley https://www.instagram.com/janebradleynyt https://www.nytimes.com/by/jane-bradley For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Open Space Event, 17 January. https://www.eventbrite.co.uk/e/road-to-gilead-open-space-event-tickets-1976897741361 Open Space in Basingstoke. https://www.proteustheatre.com/events/open-space-the-road-to-gilead/ Museum of Comedy, 13 February, 20 February, 5 March. https://www.museumofcomedy.com/the-guilty-feminist Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of The AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 464. Reform's Ties to the ADF - revisited Presented by Deborah Frances-White and Susan Wokoma with special guests Jane Bradley and Elizabeth Dias. Recorded 9 December 2025 via Riverside. Released 5 January. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Susan Wokoma https://www.instagram.com/susiewoosie12 https://www.instagram.com/p/DFK7aZDI5Sb More about Jane Bradley https://www.instagram.com/janebradleynyt https://www.nytimes.com/by/jane-bradley More about Elizabeth Dias https://www.instagram.com/elizabethjdias https://www.nytimes.com/by/elizabeth-dias For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Open Space Event, 17 January. https://www.eventbrite.co.uk/e/road-to-gilead-open-space-event-tickets-1976897741361 Open Space in Basingstoke. https://www.proteustheatre.com/events/open-space-the-road-to-gilead/ Museum of Comedy, 13 February, 20 February, 5 March. https://www.museumofcomedy.com/the-guilty-feminist Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of The AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Word of the Day with Rene Holaday for Monday, 1-5-26: Micah 7:1-20: "Sorrow for Israel's Sins, and God will Forgive Israel." Verse18 says: "He does not retain His anger forever, because He delights in mercy." Verse 14 describes "Shepherd Your people with Your staff.  the flock of Your heritage who dwell solitarily in a woodland, in the midst of Carmel; Let them feed in Bashan and Gilead, as in the days of old." We are watching the full restoration of Israel right now, just as Micah predicts here in this chapter.  Join me this morning to hear how God is a covenant God who keeps His promises and covenants.  He punished Israel for crucifying The Messiah, but He is also their redeemer who brings them back and restores them to the fullest because He delights in MERCY!  ;()  Hurray!! If any of you can help me with firewood, I could use help!  If you're blessed by this daily Bible Study and you can help me with a donation of $5 or more to my PayPal address, it certainly would be appreciated!  This next couple weeks I will be having a "FIREWOOD funds drive" so I can buy more firewood, and you can donate any amount to : reneholaday@gmail.com if you go to PayPal.com and let them know your amount and my PayPal email address.  THANK YOU ahead of time! Blessings to everyone!  ;()

Dr. Rossi interviews a long-time friend and physician about "The Balm of Gilead" and her ministry of physical and spiritual healing in the medical field.

Margaret Atwood is a Canadian writer. She has published more than sixty books spanning novels, poetry, short stories, non-fiction, children's literature, and graphic novels, and has been called “one of the sharpest and most imaginative novelists writing in English”. She is one of only four writers to have won the Booker Prize twice: for The Blind Assassin in 2000 and for her 2019 follow-up to The Handmaid's Tale, The Testaments.Margaret was born in Ottawa in November 1939, shortly after the outbreak of World War II, the second of three children to Carl Atwood, an entomologist. During her early life, she would spend the warmer months in the remote forests of northern Quebec and Ontario where her father tracked insect infestations, and the winters in the city (first Ottawa, later Toronto). She didn't attend school for a full year until the age of twelve.Her childhood scribblings – a “novel” about an ant called Annie, a volume of rhyming poems about cats, and a play about a giant – turned into a more serious ambition to become a writer when Margaret was sixteen. After studying English at the University of Toronto, where she began publishing poems in the college magazine, her first novel, The Edible Woman, came out in 1969, following five collections of poetry. Her most famous work, The Handmaid's Tale, was published in 1985 and depicted a dystopian vision of the United States as a patriarchal and totalitarian place called Gilead. Although it was written during the Reagan era, it has become eerily relevant again in the wake of the election of Donald Trump. Margaret lost her life partner, the writer Graeme Gibson, in 2019. She lives in Toronto.DISC ONE: Anchors Aweigh - US Navy Band DISC TWO: Hearts of Stone - The Charms DISC THREE: Offenbach: Les contes d'Hoffmann, Giulietta Act: Barcarolle. Belle nuit, ô nuit d'amour. Performed by Joan Sutherland (soprano) Huguette Tourangeau (soprano), Plácido Domingo (tenor), Andre Neury (bass), Pro Arte Choir, Lausanne, Choeur Du Brassus, Choeur de la Radio Suisse Romande, Orchestre de la Suisse Romande, conducted by Richard Bonynge DISC FOUR: Four Strong Winds - Ian & Sylvia DISC FIVE: Barrett's Privateers - Stan Rogers DISC SIX: The Handmaid's Tale, Act I Scene 6: The Doctor. Composed by Poul Ruders and performed by Marianne Rorholm, Hanne Fischer (Mezzo-sopranos), Royal Danish Opera Chorus and Royal Danish Orchestra, conducted by Michael Schønwandt DISC SEVEN: We Praise the Tiny Perfect Moles - Orville Stoeber DISC EIGHT: Symphony No. 6 in F Major, Op. 68 "Pastoral": II. Scene am Bach. Andante molto moto. Composed by Beethoven and performed by Philharmonia Orchestra, conducted by Otto Klemperer BOOK CHOICE: How to Survive on a Desert Island by Samantha Bell LUXURY ITEM: A knife and matchbox CASTAWAY'S FAVOURITE: Hearts of Stone - The Charms Presenter: Lauren Laverne Producer: Sarah Taylor

Welcome to The Daily, where we study the Bible verse by verse, chapter by chapter, every day. Read more about Project23 and partner with us as we teach every verse of the Bible on video. Our text today is Judges 20:1-7. Then all the people of Israel came out, from Dan to Beersheba, including the land of Gilead, and the congregation assembled as one man to the Lord at Mizpah. And the chiefs of all the people, of all the tribes of Israel, presented themselves in the assembly of the people of God, 400,000 men on foot that drew the sword. (Now the people of Benjamin heard that the people of Israel had gone up to Mizpah.) And the people of Israel said, "Tell us, how did this evil happen?" And the Levite, the husband of the woman who was murdered, answered and said, "I came to Gibeah that belongs to Benjamin, I and my concubine, to spend the night. And the leaders of Gibeah rose against me and surrounded the house against me by night. They meant to kill me, and they violated my concubine, and she is dead. So I took hold of my concubine and cut her in pieces and sent her throughout all the country of the inheritance of Israel, for they have committed abomination and outrage in Israel. Behold, you people of Israel, all of you, give your advice and counsel here." — Judges 20:1-7 The scene opens with national unity—but not spiritual unity. Israel is outraged. The murder and dismemberment of the Levite's concubine shocks them into action. Four hundred thousand men march to Mizpah, ready to make war. But notice what's missing: there's no prayer, no repentance, no seeking God's will. They are united in outrage, not obedience. They are loud about the problem, but blind to their part in it. And the Levite—the one who caused this entire mess—plays the victim. He twists the story to make himself look righteous. He never admits his cowardice or cruelty. He blames everyone but himself. This is what happens when moral outrage replaces moral conviction. It feels righteous. It sounds godly. But it's hollow—because it lacks repentance. We do the same thing today. We rage against corruption in politics, immorality in culture, and sin in society—while ignoring the idols in our own homes. We tweet truth without living it. We protest evil but excuse pride. We call for justice but never kneel for mercy. The Church must beware of becoming like Israel at Mizpah—loud in anger but silent in repentance. Before we correct the world, we must first let God correct us. The greatest threat to righteousness isn't the sin of others in the world but believers with unrepentant hearts. Revival begins with us, the righteous, getting right with God. So are you ready to remove the log from your eye? "You hypocrite, first take the log out of your own eye, and then you will see clearly to take the speck out of your brother's eye." — Matthew 7:5 ASK THIS: Where have I confused moral anger with spiritual obedience? Do I seek to fix others before I allow God to confront me? How do I respond when God exposes my hypocrisy? What would it look like to start repentance before reaction this week? DO THIS: Identify one area where your outrage exceeds your obedience—and confess it. Lead your family in a moment of prayer, asking God to purify your hearts before you judge others. Replace complaining with confession; revival always starts at home. PRAY THIS: Lord, help me see the sin beneath my outrage. Break my pride before it hardens my heart. Teach me to repent before I react, and to seek Your truth before I speak mine. Amen. PLAY THIS: "Lord, I Need You."

The Guilty Feminist 461. Homophobia and How to Fight It Presented by Deborah Frances-White and Jessica Fostkew with special guest Russell T Davies Recorded 6 December 2025 at Soho Theatre. Released 15 December. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Jessica Fostekew https://www.instagram.com/jessicafostekew More about Russell T Davies https://www.instagram.com/russelltdavies63 https://www.bbc.co.uk/programmes/m002dr53 For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Open Space Event, 17 January. https://www.eventbrite.co.uk/e/road-to-gilead-open-space-event-tickets-1976897741361 Museum of Comedy, 13 February, 20 February, 5 March. https://www.museumofcomedy.com/the-guilty-feminist Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of The AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 460. Making Our Voices Heard Presented by Deborah Frances-White and Jessica Fostkew with special guests Baroness Barker and Monica Ferro Recorded 16 November 2025 at The Museum of Comedy. Released 8 December. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have Amnesty International is the world's largest grassroots human rights organisation, working tirelessly to expose human rights abuses, hold power to account, and campaign for a fairer, safer world. We stand stronger together. Join the Amnesty International community and support their work exposing truth, debunking narratives, confronting perpetrators, defending truth-tellers and equipping communities with evidence to demand change: https://donate.giveasyoulive.com/campaign/amnesty-guilty-feminist-november-2025 More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Jessica Fostekew https://www.instagram.com/jessicafostekew More about Baroness Liz Barker https://members.parliament.uk/member/2501/contact https://www.instagram.com/p/DGQqvX3i7ZE More about Monica Ferro https://www.instagram.com/monicaferrounfpa To fight for change, we need you. Donate today and power us into 2026. https://ayzqzzms.donorsupport.co/page/buildhope For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Museum of Comedy: Friday 13 Feb, Friday 20 Feb, Thursday 5 March. Tickets on sale soon. Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of The AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 459. Christian Nationalism Presented by Deborah Frances-White and Felicity Ward with special guests Minnie Rahman and Lucy Winkett Recorded 10 November 2025 at The Pleasance London. Released 1 December. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have Amnesty International is the world's largest grassroots human rights organisation, working tirelessly to expose human rights abuses, hold power to account, and campaign for a fairer, safer world. We stand stronger together. Join the Amnesty International community and support their work exposing truth, debunking narratives, confronting perpetrators, defending truth-tellers and equipping communities with evidence to demand change: https://donate.giveasyoulive.com/campaign/amnesty-guilty-feminist-november-2025 More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Felicity Ward https://www.instagram.com/felicityward https://www.felicityward.com More about Lucy Winkett https://www.sjp.org.uk/whos-who/lucy-winkett More about Minnie Rahman https://bsky.app/profile/minnierahman.bsky.social To fight for change, we need you. Donate today and power us into 2026. https://ayzqzzms.donorsupport.co/page/buildhope For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Russell T Davies at Soho Theatre https://sohotheatre.com/events/the-guilty-feminist-9/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of The AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices